GBM91 GBM Model

Patient-derived xenograft GBM91 is a groundbreaking tool revolutionizing Brain Cancer drug development. It enables personalized testing of potential therapies, a game-changer in treatment strategies. GBM91 PDX meticulously replicates patient tumor responses, allowing researchers to predict treatment outcomes and potential toxicity accurately. By tailoring therapies to individual patient needs, GBM91 PDX paves the way for safer and more effective Brain Cancer treatments, marking a significant advancement in preclinical drug discovery.

Model Details

Cancer Location: Intracranial
Cancer Type: Brain Cancer
Model Name: GBM91
Mouse Strain: Nu/Nu
Treatment Data Available: Chemotherapy (Temozolomide)
WES: Yes
RNAseq: Yes
Methylation: Yes
PDX Treatment: Yes
Patient Treatment History: Yes

GBM91 Survival

GBM91 GBM Model

Survival of orthotopic intracranial implanted GBM91 in Nu/Nu mice (n=5)

Request Additional GBM Model Data

CONTACT US

Get Started.

Have questions about how TD2 can assist with your regulatory needs? Reach out to our expert staff today to get started.